The role of fibrosis in cardiomyopathies: An opportunity to develop novel biomarkers of disease activity
Research output: Contribution to journal › Review › Research › peer-review
Standard
The role of fibrosis in cardiomyopathies : An opportunity to develop novel biomarkers of disease activity. / Angeli, Elisavet; Jordan, Maria; Otto, Mandy; Stojanović, Stevan D.; Karsdal, Morten; Bauersachs, Johann; Thum, Thomas; Fiedler, Jan; Genovese, Federica.
In: Matrix Biology, Vol. 128, 2024, p. 65-78.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The role of fibrosis in cardiomyopathies
T2 - An opportunity to develop novel biomarkers of disease activity
AU - Angeli, Elisavet
AU - Jordan, Maria
AU - Otto, Mandy
AU - Stojanović, Stevan D.
AU - Karsdal, Morten
AU - Bauersachs, Johann
AU - Thum, Thomas
AU - Fiedler, Jan
AU - Genovese, Federica
N1 - Publisher Copyright: © 2024
PY - 2024
Y1 - 2024
N2 - Cardiomyopathies encompass a spectrum of heart disorders with diverse causes and presentations. Fibrosis stands out as a shared hallmark among various cardiomyopathies, reflecting a common thread in their pathogenesis. This prevalent fibrotic response is intricately linked to the consequences of dysregulated extracellular matrix (ECM) remodeling, emphasizing its significance in the development and progression the disease. This review explores the ECM involvement in various cardiomyopathies and its impact on myocardial stiffness and fibrosis. Additionally, we discuss the potential of ECM fragments as early diagnosis, prognosis, and risk stratification. Biomarkers deriving from turnover of collagens and other ECM proteins hold promise in clinical applications. We outline current clinical management, future directions, and the potential for personalized ECM-targeted therapies with specific focus on microRNAs. In summary, this review examines the role of the fibrosis in cardiomyopathies, highlighting the potential of ECM-derived biomarkers in improving disease management with implications for precision medicine.
AB - Cardiomyopathies encompass a spectrum of heart disorders with diverse causes and presentations. Fibrosis stands out as a shared hallmark among various cardiomyopathies, reflecting a common thread in their pathogenesis. This prevalent fibrotic response is intricately linked to the consequences of dysregulated extracellular matrix (ECM) remodeling, emphasizing its significance in the development and progression the disease. This review explores the ECM involvement in various cardiomyopathies and its impact on myocardial stiffness and fibrosis. Additionally, we discuss the potential of ECM fragments as early diagnosis, prognosis, and risk stratification. Biomarkers deriving from turnover of collagens and other ECM proteins hold promise in clinical applications. We outline current clinical management, future directions, and the potential for personalized ECM-targeted therapies with specific focus on microRNAs. In summary, this review examines the role of the fibrosis in cardiomyopathies, highlighting the potential of ECM-derived biomarkers in improving disease management with implications for precision medicine.
KW - Biomarkers
KW - Cardiomyopathies
KW - Extracellular matrix
KW - Fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85187670738&partnerID=8YFLogxK
U2 - 10.1016/j.matbio.2024.02.008
DO - 10.1016/j.matbio.2024.02.008
M3 - Review
C2 - 38423395
AN - SCOPUS:85187670738
VL - 128
SP - 65
EP - 78
JO - Matrix Biology
JF - Matrix Biology
SN - 0945-053X
ER -
ID: 386198152